Note to paragraph (a)(2)(i)(B)(3): Functional gastrointestinal disorders are a group of conditions characterized by chronic or recurrent symptoms that are unexplained by any structural, endoscopic, laboratory, or other objective signs of injury or disease and may be related to any part of the gastrointestinal tract. Specific functional gastrointestinal disorders include, but are not limited to, irritable bowel syndrome, functional dyspepsia, functional vomiting, functional constipation, functional bloating, functional abdominal pain syndrome, and functional dysphagia. These disorders are commonly characterized by symptoms including abdominal pain, substernal burning or pain, nausea, vomiting, altered bowel habits (including diarrhea, constipation), indigestion, bloating, postprandial fullness, and painful or difficult swallowing. Diagnosis of specific functional gastrointestinal disorders is made in accordance with established medical principles, which generally require symptom onset at least 6 months prior to diagnosis and the presence of symptoms sufficient to diagnose the specific disorder at least 3 months prior to diagnosis.
Table to § 3.317 -Long-Term Health Effects Potentially Associated With Infectious Diseases
A | B |
Disease | |
Brucellosis | [.] Arthritis. |
[.] Cardiovascular, nervous, and respiratory system infections. | |
[.] Chronic meningitis and meningoencephalitis. | |
[.] Deafness. | |
[.] Demyelinating meningovascular syndromes. | |
[.] Episcleritis. | |
[.] Fatigue, inattention, amnesia, and depression. | |
[.] Guillain-Barre syndrome. | |
[.] Hepatic abnormalities, including granulomatous hepatitis. | |
[.] Multifocal choroiditis. | |
[.] Myelitis-radiculoneuritis. | |
[.] Nummular keratitis. | |
[.] Papilledema. | |
[.] Optic neuritis. | |
[.] Orchioepididymitis and infections of the genitourinary system. | |
[.] Sensorineural hearing loss. | |
[.] Spondylitis. | |
[.] Uveitis. | |
Campylobacter jejuni | [.] Guillain-Barre syndrome if manifest within 2 months of the infection. |
[.] Reactive Arthritis if manifest within 3 months of the infection. | |
[.] Uveitis if manifest within 1 month of the infection. | |
Coxiella burnetii (Q fever) | [.] Chronic hepatitis. |
[.] Endocarditis. | |
[.] Osteomyelitis. | |
[.] Post-Q-fever chronic fatigue syndrome. | |
[.] Vascular infection. | |
Malaria | [.] Demyelinating polyneuropathy. |
[.] Guillain-Barre syndrome. | |
[.] Hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria). | |
[.] Immune-complex glomerulonephritis. | |
[.] Neurologic disease, neuropsychiatric disease, or both. | |
[.] Ophthalmologic manifestations, particularly retinal hemorrhage and scarring. | |
[.] Plasmodium falciparum. | |
[.] Plasmodium malariae. | |
[.] Plasmodium ovale. | |
[.] Plasmodium vivax. | |
[.] Renal disease, especially nephrotic syndrome. | |
Mycobacterium tuberculosis | [.] Active tuberculosis. |
[.] Long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis. | |
Nontyphoid Salmonella | [.] Reactive Arthritis if manifest within 3 months of the infection. |
Shigella | [.] Hemolytic-uremic syndrome if manifest within 1 month of the infection. |
[.] Reactive Arthritis if manifest within 3 months of the infection. | |
Visceral leishmaniasis | [.] Delayed presentation of the acute clinical syndrome. |
[.] Post-kala-azar dermal leishmaniasis if manifest within 2 years of the infection. | |
[.] Reactivation of visceral leishmaniasis in the context of future immunosuppression. | |
West Nile virus | [.] Variable physical, functional, or cognitive disability. |
38 C.F.R. §3.317
Authority: 38 U.S.C. 1117 , 1118